

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

ATTY DOCKET NO.
98,385-B

SERIAL NO.

09/525,998

Hauptmann et al.

FILING

March 15, 2000


GROUP

1646

U.S. PATENT DOCUMENTS

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
EPA	4,289,690	9-15-91	Pestka et al.			
	4,560,649	12-24-85	Saxena et al.			
	4,560,649	12-24-85	Saxena et al.			
	4,578,335	3-25-86	Urdal et al.			
	4,609,546	9-2-86	Hiratani			
	4,675,285	6-23-87	Clark et al.			
	4,789,658	12-6-88	Yoshimoto et al.			
	4,902,502	2-20-90	Nitecki et al.			
	4,904,584	2-27-90	Shaw			
	4,931,544	6-5-90	Katre et al.			
V	4,935,233	6-19-90	Bell et al.			

FOREIGN PATENT DOCUMENTS

4,935,233		FOREIGN PATENT DOCUMENTS				TRANSLATION	
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
 OCT 24 2000 C38 PATENT & TRADEMARK OFFICE O.I.P.E.							
Title, Date, Pertinent Pages, Etc.)							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER

Eileen B-O Hora

DATE CONSIDERED

6/11/02

EXAMINER *Alecia B-O'Hara* **DATE CONSIDERED** *6/17/03*

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


PTO-892/REV03

Patent and Trademark Office • U.S. DEPARTMENT OF COMMERCE


1 OF 17

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)			ATTY DOCKET NO. 98,385-E		SERIAL NO. 09/525,998	
			Hauptmann et al. FILING March 15, 2000		GROUP 1646	
U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
EPA	4,966,888	10-30-90	Saxena et al.			
	5,089,261	2-18-92	Nitecki et al.			
	5,116,964	5-26-92	Capon			
	5,136,021	8-4-92	Dembinski et al.			
	5,153,265	10-6-92	Shandle et al			
	5,162,430	5-25-93	Sano et al.			
	5,214,131	10-12-98	Harris et al.			
	5,252,714	10-12-93	Harris et al.			
	5,344,915	9-6-94	LeMaire et al.			
	5,359,037	10-25-94	Wallach et al.			
↓	5,382,657	1-17-95	Karasiewicz et al.			
FOREIGN PATENT DOCUMENTS						
DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
O I P E JC38 OCT 24 2008 PATENT & TRADEMARK OFFICE					YES	NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
EXAMINER EVA			DATE CONSIDERED 6/11/02			

5 VT
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				ATTY DOCKET NO. 98,385-E	SERIAL NO. 09/525,998		
				Hauptmann et al.			
FILING March 15, 2000				GROUP 1646			
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
EPA		5,395,760	3-7-95	Smith et al			
		5,478,925	12-26-95	Wallach et al.			
		5,512,544	4-30-96	Wallach et al.			
		5,605,690	2-25-97	Jacobs et al.			
		5,610,279	3-11-97	Brockhaus et al.			
		5,633,145	5-27-97	Feldmann et al.			
		5,695,953	12-9-97	Wallach et al			
		5,712,155	1-27-98	Smith et al.			
		5,808,029	9-15-98	Brockhaus et al.			
G		5,811,261	9-22-98	Wallach et al.			
		5,843,791	12-1-98	Hauptmann et al.			
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER 	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
EXAMINER <i>[Signature]</i>				DATE CONSIDERED <i>6/11/02</i>			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				ATTY DOCKET NO. 98,385-E	SERIAL NO. 09/525,998		
				Hauptmann et al.			
FILING March 15, 2000				GROUP 1646			
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
EPA		5,863,786	1-26-99	Feldmann et al.	-	-	
							
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
EPA		DE03910323A1					YES <input checked="" type="checkbox"/> NO <input type="checkbox"/>
✓		DE03913101.7					YES <input type="checkbox"/> NO <input checked="" type="checkbox"/>
✓		DE03920282.8					YES <input type="checkbox"/> NO <input checked="" type="checkbox"/>
✓		EP0154316A2					YES <input type="checkbox"/> NO <input type="checkbox"/>
✓		EP0154316B1					YES <input type="checkbox"/> NO <input type="checkbox"/>
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
EXAMINER	DATE CONSIDERED						
EPA	6/11/00						


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				ATTY DOCKET NO. 98,385-E	SERIAL NO. 09/525,998			
				Hauptmann et al.				
FILING March 15, 2000				GROUP 1646				
U.S. PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
								
FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
GA		EP0334165A2					YES	NO
↓		EP0393438A2					✓	
↓		EP0398327A1						
↓		EP0412486						
↓		EP0417563A2						
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
EXAMINER	GA	DATE CONSIDERED 6/11/02						

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION <small>(Use several sheets if necessary)</small>				ATTY DOCKET NO. 98,385-E	SERIAL NO. 09/525,998			
				Hauptmann et al.				
FILING March 15, 2000				GROUP 1646				
U.S. PATENT DOCUMENTS								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
								
FOREIGN PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
		YES	NO					
SJA		GB2218101						
↓		GB2246569A						
↓		WO90/13575						
↓		WO91/03553						
↓		WO92/01002					abstract	✓
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
EXAMINER	SJA	DATE CONSIDERED						
<i>6/11/02</i>								

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				ATTY DOCKET NO. 98,385-F	SERIAL NO. 09/525,998			
				Hauptmann et al.				
FILING March 15, 2000				GROUP 1646				
U.S. PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
								
FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
E/A		WO92/07076					YES	NO
✓		WO92/13095					YES	NO
✓		WO92/15682					YES	NO
✓		WO92/16221					YES	NO
✓		WO93/01474					YES	NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
EXAMINER	E/A	DATE CONSIDERED 6/11/02						

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION <small>(Use several sheets if necessary)</small>				ATTY DOCKET NO.	SERIAL NO.			
				98,385-E	09/525,998			
				Hauptmann et al.				
				FILING March 15, 2000	GROUP 1646			
U.S. PATENT DOCUMENTS								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
								
FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
EPA WO94/06476								
OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>								
EPA		Anderson et al., "Quantitative Filter Hybridisation," Nucleic Acid Hybridization: A Practical Approach pp. 73-111 (Hawes et al., eds., 1985).						
EPA		Aggarwal et al., "Characterization of receptors for human tumour necrosis factor and their regulation by gamma-interferon," Nature 318:665-67 (1985).						
EXAMINER EPA				DATE CONSIDERED 6/11/02				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

98,285-R

Application Number

09/525,998

Applicant(s)

Hauptmann et al.

Filing Date

March 15, 2000


Group Art Unit

1646

EXAMINER

INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EPA

 Baglioni et al., "Binding of human tumor necrosis factor to high affinity receptors on HeLa and lymphoblastoid cells sensitive to growth inhibition," J. Biol. Chem. 260:13395-97 (1985).

EPA
 Bakouche et al., "Plasma membrane-associated tumor necrosis factor. A non-integral membrane protein possibly bound to its own receptor," J. Immunol. 140:1142-47 (1988).

EPA
 Beutler et al., "Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin," Science 229:869-71 (1985).

EPA
 Binkert et al., "Cloning, sequence analysis and expression of a cDNA encoding a novel insulin-like growth factor binding protein (IGFBP-2)," EMBO J. 8:2497-502 (1989).

EPA
 Bowie et al., "Deciphering the message in protein sequences: tolerance to amino acid substitutions," Science 247:1306-10 (1990).

EPA
 Brennan et al., "Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis," Lancet 2:244-47 (1989).

EPA
 Brockhaus, M. et al., Proc. Natl. Acad. Sci. USA 87:3127-3131 (1990)

EPA
 Capaldi et al., "Changes in order of migration of polypeptides in complex III and cytochrome C oxidase under different conditions of SDS polyacrylamide gel electrophoresis," Biochem. Biophys. Res. Commun. 74:425-33 (1977)

EPA
 Carlino et al., "Use of a Sensitive Receptor Binding Assay to Discriminate Between Full-Length and Truncated Human Recombinant TNF

EPA
 Colletti et al., "The production of tumor necrosis factor alpha and the development of a pulmonary capillary injury following hepatic ischemia/reperfusion," Transplantation 49:268-72 (1990)

EPA
 Creasy, A. et al., Proc. Natl. Acad. Sci. USA 84:3293-3297 (1987)

EPA
 Dayer et al., "Purification and Characterization of Human Tumor Necrosis Factor a Inhibitor," Chemical Abstracts 113(38760n):454 (1990)

EXAMINER

EPA

DATE CONSIDERED

6/11/02

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

98,385-E

Application Number

09/525,998

Applicant(s)

Hauptmann et al.

Filing Date

March 15, 2000

Group Art Unit

1646

EXAMINER

INITIALS

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Dembic et al., "Two human TNF receptors have similar extracellular, but distinct intracellular, domain sequences," Cytokine 2:231-37 (1990).

EPA
Engelmann et al., "A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity," J. Biol. Chem. 264:11974-80 (1989).

EPA
Engelmann et al., "Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity," J. Biol. Chem. 265:14497-504 (1990).

EPA
Espesvik et al., "Characterization of binding and biological effects of monoclonal antibodies against a human tumor necrosis factor receptor," J. Exp. Med. 171:415-26 (1990).

EPA
Evans, "The steroid and thyroid hormone receptor superfamily," Science 240:889-95 (1988).

EPA
Frohman et al., "Rapid production of full-length cDNAs from rare transcripts: amplification using a single gene-specific oligonucleotide primer," Proc. Natl. Acad. Sci. U. S. A. 85:8998-9002 (1988).

EPA
Gatanaga et al., "Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotoxin...," Proc. Natl. Acad. Sci. USA 87:8781-8784 (1990).

EPA
Goodson et al., "Site-Directed Pegylation of Recombinant Interleukin-2 At Its Glycosylation Site," BioTechnology 8:343-346 (1990).

EPA
Goodwin et al., "Molecular cloning and expression of the type 1 and type 2 murine receptors for tumor necrosis factor," Mol. Cell. Biol. 11:3020-26 (1991).

EPA
Gray et al., "Cloning of human tumor necrosis factor (TNF) receptor cDNA and expression of recombinant soluble TNF-binding protein," Proc. Natl. Acad. Sci. U. S. A. 87:7380-84 (1990).

EPA
Grizzard et al., "Affinity-labeled somatomedin-C receptors and binding proteins from the human fetus," J. Clin. Endocrinol. Metab. 58:535-43 (1984).

EPA
Hale et al., "Cytokines and Their Receptors: From Clonal to Clinical Investigation, Demonstration of In Vitro and In Vivo Efficacy of Two Biologically Active Human Soluble TNF Receptors Expressed in E. Coli," J. Cell Biochem. Suppl. 15F:113(1991)

EXAMINER

EPA

DATE CONSIDERED

4/11/02

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

98,385-E

Application Number

09/525,998

Applicant(s)

Hauptmann et al.

Filing Date

March 15, 2000

Group Art Unit

1646

EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EVA
 Hass et al., "Characterization of specific high affinity receptors for human tumor necrosis factor on mouse fibroblasts," J. Biol. Chem. 260:12214-18 (1985).

EVA
 Hatakeyama et al., "Interleukin-2 receptor beta chain gene: generation of three receptor forms by cloned human alpha and beta chain cDNA's," Science 244:551-56 (1989).

EVA
 Hauser et al., "Cytokine accumulations in CSF of multiple sclerosis patients: frequent detection of interleukin-1 and tumor necrosis factor but not interleukin-6," Neurology 40:1735-39 (1990).

EVA

 Heller et al., "Amplified expression of tumor necrosis factor receptor in cells transfected with Epstein-Barr virus shuttle vector cDNA libraries," J. Biol. Chem. 265:5708-17 (1990).

EVA

 Himmeler et al., "Molecular cloning and expression of human and rat tumor necrosis factor receptor chain (p60) and its soluble derivative, tumor necrosis factor-binding protein," DNA Cell Biol. 9:705-15 (1990).

EVA
 Hofman et al., "Tumor necrosis factor identified in multiple sclerosis brain," J. Exp. Med. 170:607-12 (1989).

EVA
 Israel et al. "Binding of Human TNF-alpha to High-Affinity Cell Surface Receptors: Effect of IFN," Immunol. Lett. 12:217-224(1986).

EVA
 Kasukabe et al., "Purification of a novel growth inhibitory factor for partially differentiated myeloid leukemic cells," J. Biol. Chem. 263:5431-35 (1988).

EVA
 Kohno et al., "A Second Tumor Necrosis Factor Receptor Gene Product Can Shed a Naturally Occurring Tumor Necrosis Factor Inhibitor," Proc. Natl. Acad. Sci. USA 87:8331-8335 (1990).

EVA
 Kull et al., "Cellular receptor for 125I-labeled tumor necrosis factor: specific binding, affinity labeling, and relationship to sensitivity," Proc. Natl. Acad. Sci. U. S. A. 82:5756-60 (1985).

EVA
 Lantz et al., "Characterization in vitro of a human tumor necrosis factor-binding protein. A soluble form of a tumor necrosis factor receptor," J. Clin. Invest. 86:1396-42 (1990).

EVA
 Le et al., "Tumor necrosis factor and interleukin 1: cytokines with multiple overlapping biological activities," Lab. Invest. 56:234-48 (1987).

EXAMINER

EVA

DATE CONSIDERED

6/11/02

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

92,385-R

Application Number

09/525,998

Applicant(s)

Hauptmann et al.,

Filing Date

March 15, 2000

Group Art Unit

1646

EXAMINER

INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EPA

Lee et al., "Generation of cDNA probes directed by amino acid sequence: cloning of urate oxidase," Science 239:1288-91 (1988).

EPA


Lehmann and Droege, "Demonstration of membrane receptors for human natural and recombinant 125I-labeled tumor necrosis factor on HeLa cell clones and their role in tumor cell sensitivity," Eur. J. Biochem. 158:1-5 (1986).

EPA

Leung et al., "Growth hormone receptor and serum binding protein: purification, cloning and expression," Nature 330:537-43 (1987).

EPA

Liao et al., "Identification of a specific interleukin 1 inhibitor in the urine of febrile patients," J. Exp. Med. 159:126-36 (1984).



Liao et al., "Characterization of a Human Interleukin 1 Inhibitor," J. Immunol. 134(6):3882-3886 (1995).

Liblau et al., "Tumor Necrosis Factor-a and Disease Progression in Multiple Sclerosis," New Engl. J. Med. 326(4):272-273 (1992)

EPA

Lindvall et al., "Modulation of the constitutive gene expression of the 55 kD tumor necrosis factor receptor in hematopoietic cells," Biochem. Biophys. Res. Commun. 172:557-63 (1990).

EPA

Loetscher et al., "Recombinant 55-kDa tumor necrosis factor (TNF) receptor: Stoichiometry of binding to TNF alpha and TNF beta and inhibition of TNF activity," J. Biol. Chem. 266:18324-29 (1991).

EPA

March et al., "Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs," Nature 315:641-47 (1985).

Neda, Hiroshi, "Analysis of the Tumor Necrosis Factor (TNF) Receptor of Various Tumor Cells," Tumor Necrosis Factor, (TNF) Receptor 56(2):305-17 (1987).

EPA

Nexl et al., "Lectin-agarose immobilization, a new method for detecting soluble membrane receptors. Application to studies with epidermal growth factor-urogastrone and transcobalamin-II," J. Biol. Chem. 254:8740-43 (1979).

EPA

Nophar et al., "Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA of the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor," The EMBO J. 9(10):3269-3278 (1990).

EXAMINER

EPA

DATE CONSIDERED

6/11/02

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

92,385-E

Application Number

09/525,998

Applicant(s)

Hauptmann et al.

Filing Date

March 15, 2000

Group Art Unit

1646

EXAMINER
INITIALS

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EVA
Novick et al., "Soluble cytokine receptors are present in normal human urine," J. Exp. Med. 170:1409-14 (1989).

EVA


Novick et al., "Soluble Cytokine Receptors are Present in Normal Human Urine," The Physiological and Pathological Effects of Cytokines pp. 413-21 (1990).

EVA

Novick et al., "Purification of soluble cytokine receptors from normal human urine by ligand-affinity and immunoaffinity chromatography," J. Chromatogr. 510:331-37 (1990).

EVA

Olsson et al., "Isolation and characterization of a tumor necrosis factor binding protein from urine," Eur. J. Haematol. 42:270-75 (1989).



Peetre, C. et al., Eur. J. Haematol 41:414-419 (1988)

Peppel et al., "A Tumor Necrosis Factor (TNF) Receptor-IgG Heavy Chain Chimeric Protein as a Bivalent Antagonist of TNF Activity," J. Exp. Med. 174:1483-1489 (1991).

EVA

Piguet et al., "Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis," J. Exp. Med. 170:655-63 (1989).

Powell et al., "Lymphotoxin and tumor necrosis factor-alpha production by myelin basic protein-specific T cell clones correlates with encephalitogenicity," Int. Immunol. 2:539-44 (1990).

Rhein et al., "Another Sepsis Drug Down--Immunex TNF Receptor," Biotechnology Newswatch, pg. 1,3 (Monday, October 4, 1993).

EVA

Ruddle et al., "An Antibody to Lymphotoxin and Tumor Necrosis Factor Prevents Transfer of Experimental Allergic Encephalomyelitis," J. Exp. Med. 172:1193-1200 (1990).

EVA

Schall, T. J. et al., Cell 61:361-370 (1990)

EVA

Scheurich et al., "Quantification and characterization of high-affinity membrane receptors for tumor necrosis factor on human leukemic cell lines," Int. J. Cancer 38:127-33 (1986).

EXAMINER

EVA

DATE CONSIDERED

6/11/02

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

98,385-E

Application Number

09,525,998

Applicant(s)

Hauptmann et al.

Filing Date

March 15, 2000

Group Art Unit

1646

*EXAMINER

INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EPA

Stauber and Aggarwal, "Characterization and affinity cross-linking of receptors for human recombinant lymphotxin (tumor necrosis factor-beta) on a human histiocytic lymphoma cell line, U-937," *J. Biol. Chem.* 264:3573-76 (1989).

EPA

Suffys et al., "Involvement of a serine protease in tumour-necrosis-factor-mediated cytotoxicity," *Eur. J. Biochem.* 178:257-65 (1988).

EPA

Suggs et al., "Use of synthetic oligonucleotides as hybridization probes: isolation of cloned cDNA sequences for human beta 2-microglobulin," *Proc. Natl. Acad. Sci. U. S. A.* 78:6613-17 (1981).

EPA

The Cytokine Factsbook pp. 244-46 (Callard, ed., Academic Press, 1994).



Tracey et al., "Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation," *J. Exp. Med.* 167:1211-27 (1988).

Tracey et al., "Metabolic effects of cachectin/tumor necrosis factor are modified by site of production. Cachectin/tumor necrosis factor-secreting tumor in skeletal muscle induces chronic cachexia, while implantation in brain induces predominantly acute anorexia," *J. Clin. Invest.* 86:2014-24 (1990).

EPA

Tracey et al., "Physiological responses to cachectin," *Tumor Necrosis Factor and Related Cytotoxins* pp. 88-108 (Ciba Foundation Symposium 131, Wiley, Chichester, 1987).

Tracey et al., "Anti-Cachectin/TNF Monoclonal Antibodies Prevent Septic Shock During Lethal Bacteraemia," *Nature*

Tsujimoto et al., "Physiological responses to cachectin," *Tumor necrosis factor and related cytotoxins*. Wiley, Chichester (Ciba Foundation Symposium 131), pp. 88-108 (1987).

EPA

Unglaub et al., "Downregulation of tumor necrosis factor (TNF) sensitivity via modulation of TNF binding capacity by protein kinase C activators," *J. Exp. Med.* 166:1788-97 (1987).

EPA

Vileek et al., "Tumor necrosis factor: receptor binding and mitogenic action in fibroblasts," *J. Cell. Physiol.* 5:57-61 (1987).

Vitt et al., "Biological and Structural Characterization of the Tumor Necrosis Factor Receptor on Multiple Cell Types: Relationship to Function," *Fed. Proc.* 78th Annual Meeting of the American Society of Biological Chemists 46(6):2117 (1987).

EPA

Wallach et al., "Mechanisms which take part in regulation of the response to tumor necrosis factor," *Lymphokine Res.* 8:359-63 (1989).

EXAMINER

EPA

DATE CONSIDERED

6/11/02

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

98,385-E

Application Number

09/525,998

Applicant(s)

Hauptmann et al.

Filing Date

March 15, 2000

Group Art Unit

1646

EXAMINER

INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Wallach, "Preparations of lymphotoxin induce resistance to their own cytotoxic effect," J. Immunol. 132:2464-69 (1984).

EVA


Wallach et al., "Regulation of the Response to Tumor Necrosis Factor," pp. 134-47 (Bonavida et al., eds., Tumor Necrosis Factor/Cachectin and Related Cytokines Int. Conf. Tumor Necrosis Factor and Related Cytotoxins, Heidelberg, 1987).

EA

Walsh et al., "Isolation and purification of IL-1 inhibitor produced by human gingival epithelial cells," Clin. Exp. Immunol. 68:366-74 (1987).

EVA

Weber et al., "Production of an epidermal growth factor receptor-related protein," Science 224:294-97 (1984).



Yoshie et al., "Binding and Crosslinking of 125I-Labeled Recombinant Human Tumor Necrosis Factor to Cell Surface Receptors," J. Biochem. 100:531-541 (1986).

Ziegler, "Tumor necrosis factor in humans," N. Engl. J. Med. 318:1533-35 (1988).

EVA

EXAMINER

Eva M. O'Hara

DATE CONSIDERED

6/11/02

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.